GH Research PLC (GHRS) vs Inhibrx Biosciences Inc. (INBX)
A side-by-side comparison of GH Research PLC and Inhibrx Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GHRS
GH Research PLC
$21.47HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
INBX
Inhibrx Biosciences Inc.
$95.36HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
Total return — GHRS vs INBX
growth of $100 · dividends reinvested · last 5yGHRS +15.2% (+2.9%/yr)INBX +285.2% (+31.0%/yr)INBX compounded faster over this window
GHRS INBX
GHRS vs INBX: by the numbers
- •GHRS is the larger company ($1.47B vs $1.40B market cap).
- •Both run net losses; GHRS's is the smaller (0.00% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | GHRS | INBX |
|---|---|---|
| P/B ratio | 4.09 | N/A |
Profitability
| Metric | GHRS | INBX |
|---|---|---|
| Gross margin | 0.00% | -91.00% |
| Operating margin | 0.00% | -10386.54% |
| Net margin | 0.00% | -10773.46% |
| ROE | -17.32% | N/A |
| ROIC | -19.87% | -99.35% |
Growth (annualized)
| Metric | GHRS | INBX |
|---|---|---|
| Total return CAGR (5Y) | 0.52% | 27.64% |
Frequently asked
- How have GHRS and INBX total returns compared?
- Over the past 5 years, GHRS delivered 0.52% and INBX delivered 27.64% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.